A Modern Understanding of the Traditional and Nontraditional Biological Functions of Angiotensin-Converting Enzyme

被引:221
作者
Bernstein, Kenneth E. [1 ]
Ong, Frank S.
Blackwell, Wendell-Lamar B.
Shah, Kandarp H.
Giani, Jorge F.
Gonzalez-Villalobos, Romer A.
Shen, Xiao Z.
Fuchs, Sebastien
机构
[1] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA
基金
美国国家卫生研究院;
关键词
ASPARTYL-LYSYL-PROLINE; KALLIKREIN-KININ SYSTEM; II-INDUCED HYPERTENSION; ACE GENE POLYMORPHISM; 2 HOMOLOGOUS DOMAINS; MEDIATED MICROVASCULAR THROMBOSIS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; BRADYKININ-POTENTIATING PEPTIDES; TISSUE-SPECIFIC EXPRESSION; TERMINAL CATALYTIC DOMAIN;
D O I
10.1124/pr.112.006809
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Angiotensin-converting enzyme (ACE) is a zinc-dependent peptidase responsible for converting angiotensin I into the vasoconstrictor angiotensin II. However, ACE is a relatively nonspecific peptidase that is capable of cleaving a wide range of substrates. Because of this, ACE and its peptide substrates and products affect many physiologic processes, including blood pressure control, hematopoiesis, reproduction, renal development, renal function, and the immune response. The defining feature of ACE is that it is composed of two homologous and independently catalytic domains, the result of an ancient gene duplication, and ACE-like genes are widely distributed in nature. The two ACE catalytic domains contribute to the wide substrate diversity of ACE and, by extension, the physiologic impact of the enzyme. Several studies suggest that the two catalytic domains have different biologic functions. Recently, the X-ray crystal structure of ACE has elucidated some of the structural differences between the two ACE domains. This is important now that ACE domain-specific inhibitors have been synthesized and characterized. Once widely available, these reagents will undoubtedly be powerful tools for probing the physiologic actions of each ACE domain. In turn, this knowledge should allow clinicians to envision new therapies for diseases not currently treated with ACE inhibitors.
引用
收藏
页码:1 / 46
页数:46
相关论文
共 521 条
[1]
Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis [J].
AbdAlla, S ;
Lother, H ;
Langer, A ;
el Faramawy, Y ;
Quitterer, U .
CELL, 2004, 119 (03) :343-354
[2]
ACE revisited: A new target for structure-based drug design [J].
Acharya, KR ;
Sturrock, ED ;
Riordan, JF ;
Ehlers, MRW .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (11) :891-902
[3]
ACE gene polymorphism in cardiovascular disease -: Meta-analyses of small and large studies in whites [J].
Agerholm-Larsen, B ;
Nordestgaard, BG ;
Tybjaerg-Hansen, A .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) :484-492
[4]
ACE gene polymorphism: Ischemic heart disease and longevity in 10150 individuals - A case-referent and retrospective cohort study based on the Copenhagen City Heart Study [J].
AgerholmLarsen, B ;
Nordestgaard, BG ;
Steffensen, R ;
Sorensen, TIA ;
Jensen, G ;
TybjaergHansen, A .
CIRCULATION, 1997, 95 (10) :2358-2367
[5]
Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease [J].
Ahmed, Ali ;
Fonarow, Gregg C. ;
Zhang, Yan ;
Sanders, Paul W. ;
Allman, Richard M. ;
Arnett, Donna K. ;
Feller, Margaret A. ;
Love, Thomas E. ;
Aban, Inmaculada B. ;
Levesque, Raynald ;
Ekundayo, O. James ;
Dell'Italia, Louis J. ;
Bakris, George L. ;
Rich, Michael W. .
AMERICAN JOURNAL OF MEDICINE, 2012, 125 (04) :399-410
[6]
Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction [J].
Ainscough, Justin F. X. ;
Drinkhill, Mark J. ;
Sedo, Alicia ;
Turner, Neil A. ;
Brooke, David A. ;
Balmforth, Anthony J. ;
Ball, Stephen G. .
CARDIOVASCULAR RESEARCH, 2009, 81 (03) :592-600
[7]
High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients [J].
Albitar, S ;
Genin, R ;
Fen-Chong, M ;
Serveaux, MO ;
Bourgeon, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (05) :1206-1210
[8]
The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein [J].
Allinson, TMJ ;
Parkin, ET ;
Condon, TP ;
Schwager, SLU ;
Sturrock, ED ;
Turner, AJ ;
Hooper, NM .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2004, 271 (12) :2539-2547
[9]
Anthony CS, 2012, CURR MED CHEM, V19, P845
[10]
The N Domain of Human Angiotensin-I-converting Enzyme THE ROLE OF N-GLYCOSYLATION AND THE CRYSTAL STRUCTURE IN COMPLEX WITH AN N DOMAIN-SPECIFIC PHOSPHINIC INHIBITOR, RXP407 [J].
Anthony, Colin S. ;
Corradi, Hazel R. ;
Schwager, Sylva L. U. ;
Redelinghuys, Pierre ;
Georgiadis, Dimitris ;
Dive, Vincent ;
Acharya, K. Ravi ;
Sturrock, Edward D. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (46) :35685-35693